[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone; methanesulfonic acid

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

45 API Suppliers, 12 USDMF, 10 CEP/COS, 6 JDMF, 7 EU WC, 5 KDMF, 7 NDC API, 21 Listed Suppliers, $ API Reference Price

INTERMEDIATES

19 Intermediate Suppliers

19 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

316 FDF Dossiers, 82 FDA Orange Book, 194 Europe, 12 Canada, 1 South Africa, 27 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 1MG BASE, TABLET;ORAL - EQ 2MG BASE, TABLET;ORAL - EQ 4MG BASE, TABLET;ORAL - EQ 8MG BASE, TABLET, EXTENDED RELEASE;ORAL - EQ 4MG BASE, TABLET, EXTENDED RELEASE;ORAL - EQ 8MG BASE

RELATED EXCIPIENT COMPANIES

4 SPI Pharma, 6 DKSH, 5 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 Kirsch Pharma, 1 ACG Worldwide, 5 Actylis, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 15 BASF, 1 CD Formulation, 10 Corel Pharma Chem, 7 DFE Pharma, 1 Esteem Industries, 1 Finar, 6 Gangwal Chemicals, 4 Ideal Cures, 4 Ingredion Pharma Solutions, 24 Kerry, 3 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 11 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 1 Novo Excipients, 2 Pharmatrans-Sanaq, 5 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 18 Roquette, 7 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 10 Sigachi Industries, 4 Silverline Chemicals, 2 The Dow Chemical Company, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

42 Coating Systems & Additives, 41 Fillers, Diluents & Binders, 27 Direct Compression, 26 Disintegrants & Superdisintegrants, 26 Granulation, 19 Controlled & Modified Release, 18 Thickeners and Stabilizers, 13 Lubricants & Glidants, 10 Co-Processed Excipients, 9 Taste Masking, 9 Topical, 8 Chewable & Orodispersible Aids, 6 Film Formers & Plasticizers, 5 Empty Capsules, 5 Coloring Agents, 5 Solubilizers, 5 Rheology Modifiers, 4 Parenteral, 4 Vegetarian Capsules, 4 API Stability Enhancers, 4 Emulsifying Agents, 1 Surfactant & Foaming Agents

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 12 News #PharmaBuzz

GLOBAL SALES INFORMATION

12 US Medicaid Prescriptions, 153 Regulatory FDF Prices, 3 Annual Reports

MARKET PLACE

7 APIs, 2 FDF Dossiers, 1 Intermediates

REF. STANDARDS & IMPURITIES

3 EDQM, 4 JP, 11 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 21269 / DOSAGE - TABLET, EXTENDED RELEASE;ORAL - EQ 4MG BASE

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
DOXAZOSIN MESYLATE(UNII: 86P6PQK0MU) (DOXAZOSIN - UNII:NW1291F1W8)	DOXAZOSIN	8mg \| 8mg \| 4mg \| 4mg

Inactive Ingredients

Ingredient Name	Roerig
CELLULOSE ACETATE(3J2P07GVB6)
FERRIC OXIDE RED(1K09F3G675)
FERROSOFERRIC OXIDE(XM0M87F357)
HYPROMELLOSE, UNSPECIFIED(3NXW29V3WO)
MAGNESIUM STEARATE(70097M6I30)
POLYETHYLENE GLYCOL, UNSPECIFIED(3WJQ0SDW1A)
SODIUM CHLORIDE(451W47IQ8X)
TITANIUM DIOXIDE(15FIX9V2JP)

Setid Cfbb4ddc 00e9 403e 8529 41eb96b81618 Applno 21269 Form Tablet Extended Release Oral Dosage Eq 4mg Base - Drug Product Composition: [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone; methanesulfonic acid